NexImmune, Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Gaithersburg, MD
SEC filing record 1 source field available
Fiscal year end
31 December
NexImmune, Inc. has filed 217 SEC EDGAR filings since 03 Feb 2012

SEC filing history

Showing 176-200 of 217 matching filings.

Per page
25
Current page
8
4

FORM 4 SUBMISSION

Filing date
16 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
SEC STAFF LETTER

SEC STAFF LETTER filing

Filing date
11 Feb 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-252220

EFFECT filing

Filing date
11 Feb 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-1MEF File 333-253021

S-1MEF

Filing date
11 Feb 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
11 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
11 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
11 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
11 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
11 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
11 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
11 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
11 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
11 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
11 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
11 Feb 2021
Reporting date
11 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
S-1/A File 333-252220

S-1/A

Filing date
11 Feb 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
CERT File 001-40045

8A CERT

Filing date
10 Feb 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .